This Study is Mainly About Finding Incidence Among Other Factors of Thyroid Cancer in Patient with Benign Disease As MNG to Early Discover of the Malignancy to Save the Patient from Aggressive Procedure
- Sponsor
- Asmaa Mohamed Emam
- Study ID
- NCT06730971
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Thyroid Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Total thyroidectomy — PROCEDUREPost operative specimen after total thyroidectomy
- Total thyroidectomy — PROCEDURERemove of both thyroid lobes and isthmus
Study Details
The purpose of the present study was to evaluate the prevalence of thyroid cancer in patients who had thyroidectomy for MNG, and analyze patient-related parameters to identify type and risk factors associated with incidental thyroid malignancy.
Key Dates
- First listed
- Dec 12, 2024
- Start date
- Dec 31, 2024
- Status verified
- Dec 2024
- Primary completion
- Jun 30, 2026
- Completion
- Oct 31, 2026
Study Design
- Enrollment
- 300 participants (estimated)
Primary Outcome Measure
Evaluate the prevalence of Incidental thyroid cancer (ITC) in patients who had thyroidectomy for MNG, and analyze patient-related parameters to identify type and risk factors associated with incidental thyroid malignancy. [ Time Frame: 1 month ]
Central Contacts
- Asmaa Emam
Related Studies
- Studies on Tumors of the ThyroidRecruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
- Integrated Cancer Repository for Cancer ResearchRecruiting · University of Nebraska · Greenwood Village, Colorado
- Hereditary Risk Factors for Thyroid CancerRecruiting · Dana-Farber Cancer Institute · Boston, Massachusetts
- APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid TumorsPHASE2 · Recruiting · Apollomics Inc. · Los Angeles, California